Research indicates that agents with different mechanisms of action, impacting cancer cells in multiple ways, provide improved clinical benefit and decrease the risk of relapse. This is precisely why Xcovery is focused on developing next-generation tyrosine kinase inhibitors (TKIs). TKIs with increased efficacy and reduced toxicity can be used alone, sequentially, or in combination with other agents and therefore address the therapeutic challenge of intrinsic and acquired treatment resistance.

  • Ensartinib, an ALK inhibitor, is potentially a new best-in-class TKI for the first-line treatment of ALK-positive non-small cell lung cancer.
  • Vorolanib is a new multi-kinase inhibitor that is an ideal drug for use in combination with other compounds. Many oncology agents currently on the market provide modest clinical benefit as monotherapy. Because of the complexity of cancer, combinations often prove more effective than single agents by attacking more than 1 molecular pathway.


combo, combination; IO, immuno-oncology; NSCLC, non-small cell lung cancer; Ph, phase; RCC, renal cell cancer; ROS1, ROS proto-oncogene 1, receptor tyrosine kinase; SCLC, small cell lung cancer.

Investigational Agents

Xcovery is participating in the NCI Formulary, a public-private partnership between the National Cancer Institute (NCI), part of the National Institutes of Health (NIH), and pharmaceutical and biotechnology companies to expedite the use of investigational agents in clinical trials.

Expanded Access Policy

Xcovery is open to working with investigators who are seeking expanded access treatment for their patients. Eligible centers include those that currently have investigators conducting ensartinib-related trials in the United States. A list of the investigators can be found on the website (search for ensartinib or X-396). Patients with inquiries regarding expanded access treatment should first consult with their oncologists.